I
ImmuCell Corporation (ICCC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$11.42
+0.67 (+6.23%)
Market Cap: $97.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
ImmuCell Corporation (ICCC) P/E Ratio & Valuation History
ImmuCell (ICCC) trades at 57.2x trailing earnings and 3.1x sales. Its P/S of 3.1x is above its 5-year median of 2.3x.
Current Multiples
Its enterprise value is 25.3x its EBITDA. Its free cash flow yield is 5.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 57.2x |
| Forward P/E | N/A |
| Price to sales | 3.1x |
| Price to book | 3.2x |
| EV/EBITDA | 25.3x |
| Price to FCF | 19.2x |
| EV/FCF | 19.2x |
| PEG | N/A |
| FCF yield | 5.2% |
Historical Medians
Against its 10-year medians, its P/S is 19.2% above 2.6x and its P/B is 100.0% above 1.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.1x | 2.3x | 2.6x |
| P/B | 3.2x | 1.7x | 1.6x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.6x in 2024 to 4.2x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.15 | N/A | 2.0x | 2.1x |
| 2024 | $5.15 | N/A | 1.6x | 1.7x |
| 2023 | $5.09 | N/A | 2.3x | 1.5x |
| 2022 | $6.10 | N/A | 2.5x | 1.6x |
| 2021 | $8.00 | N/A | 3.2x | 1.9x |
| 2020 | $5.95 | N/A | 2.8x | 1.5x |
| 2019 | $5.15 | N/A | 2.3x | 1.0x |
| 2018 | $7.05 | N/A | 3.5x | 1.8x |
| 2017 | $8.79 | N/A | 4.2x | 1.9x |
| 2016 | $5.95 | 46.9x | 2.6x | 1.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ICCC
Is ICCC stock overvalued?
GNG's valuation label for ICCC is Fairly valued.
What is ICCC's price to sales ratio?
ImmuCell has a price to sales ratio of 3.1x.
ICCC pages: Overview, Earnings, Financials, Valuation, Competitors